Welcome to our dedicated page for Catheter Precision news (Ticker: VTAK), a resource for investors and traders seeking the latest updates and insights on Catheter Precision stock.
Catheter Precision, Inc. reports developments across cardiac electrophysiology medical devices and regional air mobility. The company’s medical technology updates center on VIVO, a non-invasive 3D imaging system for identifying ventricular arrhythmia origins before electrophysiology procedures, and LockeT, a suture retention device for wound closure after percutaneous venous punctures.
Recurring VTAK news also covers FDA and CE Mark status, clinical publications, medical conference activity, patent protection, product commercialization, and Flyte, its regional air mobility subsidiary. Flyte operates Cirrus Vision Jets for short-haul markets through an FAA-certified Part 135 air carrier platform.
Catheter Precision (NYSE:VTAK), a US-based medical device company, has announced the successful completion of its first LockeT cases in Germany at Zentralklinik Bad Berka, one of Thuringia's largest hospitals.
The medical team has successfully conducted 10 cases using LockeT to close single or multiple punctures with a single device per case. The procedures demonstrated LockeT's versatility by handling sheath sizes ranging from 6F to 17Fr. The company views Germany as a significant European market opportunity, particularly due to its price-conscious nature.
Catheter Precision (NYSE:VTAK), a medical device company specializing in cardiac electrophysiology, reported significant growth in Q2 2025. Revenue surged 128% year-over-year to $212,000 and 48% sequentially. The company achieved several milestones, including receiving CE Mark for LockeT and completing strategic acquisitions.
Notable clinical achievements include successful trials demonstrating VIVO's 94% accuracy in non-invasive localization and 83% long-term procedural success. The company formed Kardionav, Inc. for developing implant-based software for ventricular tachyarrhythmia treatment. However, the company reported a net loss of $5.4 million for Q2 2025, with $3.2 million in non-cash charges, and maintained a cash position of $838,000.
Catheter Precision (NYSE:VTAK) announced that the Heart Hospital of New Mexico has achieved a significant milestone by completing 200 ventricular ablation procedures using the company's VIVO system. The Heart Hospital, part of the Lovelace Health system, is New Mexico's only hospital dedicated exclusively to cardiovascular care.
The Lovelace Health system encompasses five hospitals, 33 health care clinics, and seven outpatient therapy clinics with over 300 healthcare providers. The hospital's physician team has published data and facilitated educational initiatives for other physicians regarding the VIVO technology.
Catheter Precision (NYSE:VTAK) has secured its largest purchase order to date for its VIVO product line from Centre Hospitalier Universitaire (CHU) de Rennes in France. The hospital, which serves approximately 500,000 patients annually, performs over 150 ventricular ablations per year, making it one of Europe's largest ventricular ablation centers.
CEO David Jenkins emphasized the strategic importance of partnering with teaching hospitals to introduce their products to physicians early in their careers, which could lead to long-term product adoption.
Catheter Precision (NYSE:VTAK) has announced the formation of a new joint venture called Kardionav to develop advanced AI-powered software for ventricular tachycardia (VT) ablation. The venture combines VTAK's expertise with Chelak iECG to enhance VT treatment outcomes through improved mapping technology.
The ownership structure allocates 56% to VTAK, 33% to Chelak iECG, and 10% to management. Dr. Jie Cheng, founder of Chelak iECG and Clinical Professor at Baylor College of Medicine, will serve as the primary researcher, bringing significant AI and arrhythmia localization expertise to the venture.
The joint venture aims to develop a standalone ventricular mapping system that will integrate vector technology with imaging of conduction channels and velocity calculations. This next-generation technology builds upon VTAK's existing VIVO platform and seeks to address current limitations in VT ablation procedures, including lengthy procedure times and imprecise ablation site targeting.
Catheter Precision (NYSE American: VTAK) has received CE Mark approval for LockeT, its advanced vascular closure device, enabling market access in the EU, UK, Switzerland, and Turkey. The European Vascular Closure Devices Market, valued at $3.1 billion in 2024, is projected to reach $4.3 billion by 2028 with a 7% CAGR.
The company has already secured its first order of 100 units and is in discussions with multiple distribution partners. LockeT offers economic advantages over competing products and features easy deployment, patient comfort, and intuitive recovery nursing processes.